This is an ancillary study of the Phase II multicenter, randomized, placebo-controlled trial of hydroxyurea therapy for sickle cell disease. Both UNC and Duke are taking part in this trial. During Phase I of the study, 26 of the 32 patients treated gained weight. This study will make use of the opportunity provided by a Phase II study to investigate the etiology, tissue composition, and any change in muscle function that accompanies weight gain associated with HU therapy.
Showing the most recent 10 out of 782 publications